About: http://data.cimple.eu/news-article/4530c4af9cea3179a915cb5ea89b1a9cfb93508a316e3eac2a4af052     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • French pharmaceutical giant Sanofi said Tuesday that it would invest $425 million to expand its vaccine development venture with US start-up Translate Bio as they aim to find a COVID-19 vaccine by next year. The companies have been working together since 2018, hoping to leverage Translate Bio's work on new messenger RNA (mRNA) drugs that cause cells to create a specific protein for treating a range of diseases. Their work has taken on greater urgency with the coronavirus pandemic, as pharma groups race to be the first to offer a vaccine to halt an outbreak that has killed nearly 470,000 people worldwide since December. In a statement, Sanofi said they have "multiple COVID-19 vaccine candidates" in the works and hope to start a clinical trial with humans in the fourth quarter of this year. "We believe that adding this mRNA platform to our vaccines development capabilities will help us advance prevention against current and future infectious diseases," said Thomas Triomphe, executive vice president at Sanofi Pasteur, the firm's vaccines unit. Sanofi CEO Paul Hudson told journalists on Monday that his firm's most promising COVID-19 treatment is "the only vaccine in the race which is offering a proven platform which works at scale." "We are a little bit slower but we are much more likely to have success," he said at a briefing ahead of Sanofi's investor day Tuesday. Hudson drew the ire of French officials last month when he suggested that any COVID-19 vaccine would be offered first to the US government, which has invested millions in its development by the company. Under pressure, he later indicated that it would be available to everyone at the same time and he announced a new 490 million euro vaccine production site in France last week while touring a facility with President Emmanuel Macron. "We're making vaccines in Europe and we're making vaccines in the US, so we anticipate having vaccines simultaneously available in many markets," Hudson said Monday. lem/js/bmm
schema:headline
  • Sanofi expands US vaccine venture in COVID-19 race
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software